Received Mar 7, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| PNC15 | PNEUMO (VAXNEUVANCE) | MERCK & CO. INC. | 3 | Y005465 | — |
| RV5 | ROTAVIRUS (ROTATEQ) | MERCK & CO. INC. | 3 | Y005878 | OT |
No additional AE reported; VFC immunization coordinator calling to report T/E for ROTATEQ, and VAXNEUVANCE that was administered. T/E date was on 2/18/2025 and ROTATEQ and VAXNEUVANCE were administered on 2/25/2025. Permission was given to contact HCP by email. No addition; This spontaneous report has been received from a nurse regarding a patient of unknown age and gender. The patient's medical history, concurrent conditions, and concomitant therapies were not reported. On 25-FEB-2025, the patient was vaccinated with the third dose of Pneumococcal 15-valent Conjugate Vaccine (VAXNEUVANCE) 0.5 mL Injection, administered as prophylaxis (lot number reported as Y005465, which has been verified as valid, expiration date reported and validated as 08-JAN-2027) (dose, route of administration, and anatomical site of injection were not provided); and with the third dose of Rotavirus Vaccine, Live, Oral, Pentavalent (ROTATEQ), Oral suspension, administered orally as prophylaxis (lot number reported as Y005878, which has been verified as valid, expiration date reported and validated as 28-OCT-2025) (strength and dose were not provided). The administered doses were exposed to a temperature excursion of 32 Fahrenheit degrees (F) for 2 hours and 12 minutes (Product storage error). No additional adverse events were reported.